In Vivo Imaging of COPD with technetium labelled antibodies (INVICTA)
Research type
Research Study
Full title
In Vivo Imaging of COPD with technetium labelled antibodies (INVICTA)
IRAS ID
239426
Contact name
Shauna Marshall
Contact email
Sponsor organisation
University Hospital Southampton
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Chronic obstructive pulmonary disease (COPD) is a common lung disease that is usually caused by cigarette smoking. Different methods and techniques are needed to investigate the disease in more detail, which may help us manage and treat the condition more effectively.
INVICTA is a study to investigate a new imaging technique in patients with chronic obstructive pulmonary disease (COPD). This imaging technique is called a Single Positron Emission Computed Tomography Scan (SPECT-CT) and this will be used to detect the uptake of a drug (infliximab) labelled with a radioactive material within the lungs after being injected into study subjects. Five subjects with COPD and five healthy subjects will be recruited into the study and will undergo this imaging technique. This will then be used to investigate changes within the lung in COPD that will hopefully improve our understanding of the condition.
In the future this may help to develop new treatments for patients with this disease. The imaging technique may also be useful in investigating lung diseases other than COPD.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
18/SC/0359
Date of REC Opinion
24 Sep 2018
REC opinion
Further Information Favourable Opinion